APP Gene-Based Strategies to Combat Alzheimer's Disease in Down Syndrome

References

1. Ballard C. Mobley W. Hardy J. Williams G. Corbett A. Dementia in Down’s syndrome. Lancet Neurol. 2016 15 6 622 636 10.1016/S1474‑4422(16)00063‑6 27302127
   [Google Scholar]
2. Selkoe D.J. Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 2016 8 6 595 608 10.15252/emmm.201606210 27025652
   [Google Scholar]
3. Doran E. Keator D. Head E. Phelan M.J. Kim R. Totoiu M. Barrio J.R. Small G.W. Potkin S.G. Lott I.T. Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: The role of APP. J. Alzheimers Dis. 2017 56 2 459 470 10.3233/JAD‑160836 27983553
   [Google Scholar]
4. Chen X.Q. Salehi A. Pearn M.L. Overk C. Nguyen P.D. Kleschevnikov A.M. Maccecchini M. Mobley W.C. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimers Dement. 2021 17 2 271 292 10.1002/alz.12185 32975365
   [Google Scholar]
5. Bandyopadhyay S. Cahill C. Balleidier A. Huang C. Lahiri D.K. Huang X. Rogers J.T. Novel 5′ untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: Implications for down syndrome and Alzheimer’s disease. PLoS One 2013 8 7 e65978 10.1371/journal.pone.0065978 23935819
   [Google Scholar]
6. Galasko D. Farlow M.R. Lucey B.P. Honig L.S. Elbert D. Bateman R. Momper J. Thomas R.G. Rissman R.A. Pa J. Aslanyan V. Balasubramanian A. West T. Maccecchini M. Feldman H.H. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimers Res. Ther. 2024 16 1 151 10.1186/s13195‑024‑01490‑z 38970127
   [Google Scholar]
7. Chang J.L. Hinrich A.J. Roman B. Norrbom M. Rigo F. Marr R.A. Norstrom E.M. Hastings M.L. Targeting amyloid-β precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-β production. Mol. Ther. 2018 26 6 1539 1551 10.1016/j.ymthe.2018.02.029 29628304
   [Google Scholar]
8. Hung C. Fertan E. Livesey F.J. Klenerman D. Patani R. APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer’s disease. Brain 2024 147 7 2325 2333 10.1093/brain/awae092 38527856
   [Google Scholar]
9. Nordvall G. Lundkvist J. Sandin J. Gamma-secretase modulators: A promising route for the treatment of Alzheimer’s disease. Front. Mol. Neurosci. 2023 16 1279740 10.3389/fnmol.2023.1279740 37908487
   [Google Scholar]
10. Rynearson K.D. Ponnusamy M. Prikhodko O. Xie Y. Zhang C. Nguyen P. Hug B. Sawa M. Becker A. Spencer B. Florio J. Mante M. Salehi B. Arias C. Galasko D. Head B.P. Johnson G. Lin J.H. Duddy S.K. Rissman R.A. Mobley W.C. Thinakaran G. Tanzi R.E. Wagner S.L. Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention. J. Exp. Med. 2021 218 4 e20202560 10.1084/jem.20202560 33651103
    [Google Scholar]
11. Wagner S.L. Rynearson K.D. Duddy S.K. Zhang C. Nguyen P.D. Becker A. Vo U. Masliah D. Monte L. Klee J.B. Echmalian C.M. Xia W. Quinti L. Johnson G. Lin J.H. Kim D.Y. Mobley W.C. Rissman R.A. Tanzi R.E. Pharmacological and toxicological properties of the potent oral γ-secretase modulator BPN-15606. J. Pharmacol. Exp. Ther. 2017 362 1 31 44 10.1124/jpet.117.240861 28416568
    [Google Scholar]
12. Prikhodko O. Rynearson K.D. Sekhon T. Mante M.M. Nguyen P.D. Rissman R.A. Tanzi R.E. Wagner S.L. The GSM BPN-15606 as a potential candidate for preventative therapy in Alzheimer’s disease. J. Alzheimers Dis. 2020 73 4 1541 1554 10.3233/JAD‑190442 31958080
    [Google Scholar]
13. Chen X.Q. Becker A. Albay R. Nguyen P.D. Karachentsev D. Roberts A.J. Rynearson K.D. Tanzi R.E. Mobley W.C. γ-secretase modulator BPN15606 reduced Aβ42 and Aβ40 and countered alzheimer-related pathologies in a mouse model of down syndrome. Ann. Neurol. 2024 96 2 390 404 10.1002/ana.26958 38747498
    [Google Scholar]
14. Cummings J. Osse A.M.L. Cammann D. Powell J. Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs 2024 38 1 5 22 10.1007/s40259‑023‑00633‑2 37955845
    [Google Scholar]
15. Belichenko P.V. Madani R. Rey-Bellet L. Pihlgren M. Becker A. Plassard A. Vuillermot S. Giriens V. Nosheny R.L. Kleschevnikov A.M. Valletta J.S. Bengtsson S.K. Linke G.R. Maloney M.T. Hickman D.T. Reis P. Granet A. Mlaki D. Lopez-Deber M.P. Do L. Singhal N. Masliah E. Pearn M.L. Pfeifer A. Muhs A. Mobley W.C. An anti-β-amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome. PLoS One 2016 11 3 e0152471 10.1371/journal.pone.0152471 27023444
    [Google Scholar]
16. Rafii M.S. Sol O. Mobley W.C. Delpretti S. Skotko B.G. Burke A.D. Sabbagh M.N. Yuan S.H. Rissman R.A. Pulsifer M. Evans C. Evans A.C. Beth G. Fournier N. Gray J.A. Dos Santos A.M. Hliva V. Vukicevic M. Kosco-Vilbois M. Streffer J. Pfeifer A. Feldman H.H. Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with down syndrome: A phase 1b randomized clinical trial. JAMA Neurol. 2022 79 6 565 574 10.1001/jamaneurol.2022.0983 35532913
    [Google Scholar]